Clinical trials
Cardiomyopathies clinical trials
Below are recruiting cardiomyopathies clinical trials, each written for real people, not researchers. We’re tracking 322 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07077005Recruiting
Can Mavacamten Help You Exercise More?
This study looks at whether taking mavacamten for at least 12 weeks helps people with a certain type of heart disease (hypertrophic obstructive cardiomyopathy) exercise better. You'll have tests to check your heart's function and safety during exercise.
Munich, BavariaAges 18–99 - NCT07137338RecruitingPhase 1
Gene therapy for BAG3-related dilated cardiomyopathy
This trial tests a one-time gene therapy called RP-A701 for people with dilated cardiomyopathy caused by a BAG3 gene mutation. The goal is to see if it is safe and can improve heart function.
San Diego, CaliforniaAges 18–65 - NCT07150299Recruiting
How heart medications affect blood flow in hypertrophic cardiomyopathy
This study looks at how heart medications affect blood flow in people with obstructive hypertrophic cardiomyopathy. You will have a heart MRI before and after starting or adjusting treatment to see how your heart responds.
ViennaAges 18 years+ - NCT07202897RecruitingPhase 3
Preventing blood clots in hypertrophic cardiomyopathy with rivaroxaban
This trial tests if the blood thinner rivaroxaban can prevent strokes in people with hypertrophic cardiomyopathy who have early signs of damage in their left atrium (the heart's upper chamber). You may qualify if you have this condition, are in a normal heart rhythm, and are between 40 and 80 years old.
AngersAges 40–80 - NCT07235462Recruiting
Acoramidis for heart disease due to TTR amyloidosis
This study follows people with a heart condition called transthyretin amyloid cardiomyopathy (ATTR-CM) who are starting treatment with acoramidis. It aims to see how well the medicine works in everyday medical practice.
HeidelbergAges 18 years+ - NCT07240844RecruitingPhase 4
Enavogliflozin for amyloid heart disease
This study tests a drug called enavogliflozin to see if it helps people with a specific type of heart failure caused by amyloid buildup. It may improve symptoms and daily function.
SeoulAges 19 years+ - NCT07241104RecruitingPhase 1
Study of AZD4063 for PLN R14del dilated cardiomyopathy
This trial tests a new drug called AZD4063 for people with dilated cardiomyopathy caused by a specific genetic change (PLN R14del mutation). The goal is to see if the drug can improve heart function, and it requires participants to have an ICD or CRT-D device.
AmsterdamAges 18–80 - NCT07516288RecruitingPhase 1
Second CAR-DC Cell Infusion for Advanced Heart Failure
This trial tests a second dose of specialized immune cells (called CAR-DC) in patients with severe dilated cardiomyopathy (a weakened heart muscle) who received one dose before but saw their heart function decline back to baseline. The goal is to see if a second dose is safe and can improve heart function when the first treatment's benefits wore off.
Hangzhou, Zhejiang / 浙江Ages 18–75 - NCT07263204Recruiting
AI for diagnosing and predicting hypertrophic cardiomyopathy
This trial uses artificial intelligence to help diagnose and predict outcomes for people with hypertrophic cardiomyopathy (HCM), a condition where the heart muscle becomes thickened. It may help doctors better understand your condition and plan your care.
Hangzhou, ZhejiangAges 18 years+ - NCT07293338Recruiting
Heart muscle blood flow study for dilated cardiomyopathy
This study looks at how small blood vessels in the heart affect outcomes in people with dilated cardiomyopathy (an enlarged, weak heart). You may qualify if you have heart failure with a weak pump and no significant blockages in your main heart arteries.
Hangzhou, ZhejiangAges 18 years+ - NCT07336394Recruiting
Study on rare heart muscle diseases using advanced MRI
This study uses a special heart MRI to better diagnose and understand rare heart muscle diseases. It may help doctors predict risks and make more accurate treatment decisions.
BeijingAges Any age - NCT07344480Recruiting
Study on heart disease in children with RASopathy
This study looks at medical records of children with a genetic condition called RASopathy who developed thickened heart muscle and needed hospital care for heart failure in their first six months of life. The goal is to understand how the heart condition progresses over time.
MünchenAges Any age - NCT07361289Recruiting
Mavacamten for obstructive hypertrophic cardiomyopathy in China
This study looks at how well mavacamten works in real life for adults with obstructive hypertrophic cardiomyopathy, a condition where the heart muscle is thickened and blocks blood flow. It may help improve symptoms like shortness of breath or chest pain.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07367724RecruitingPhase 2
Ademetionine for obstructive hypertrophic cardiomyopathy
This trial tests a medication called Ademetionine for people with obstructive hypertrophic cardiomyopathy (a condition where the heart muscle is thick and blocks blood flow). It aims to see if the drug can help improve symptoms and exercise ability.
BeijingAges 18 years+ - NCT07372196Recruiting
Left bundle branch pacing after myectomy for hypertrophic cardiomyopathy
This trial is testing a new way to pace the heart (left bundle branch pacing) for people with hypertrophic cardiomyopathy who still have a dangerous heart rhythm problem after myectomy surgery. It aims to see if this pacing can reduce the risk of sudden cardiac death.
Novosibirsk, Novosibirsk OblastAges 18–75 - NCT07381894Recruiting
Hypertrophic cardiomyopathy patient registry
This registry collects information about people with hypertrophic cardiomyopathy (HCM) to better understand the condition and improve care. It is for patients who have a confirmed HCM diagnosis not caused by other issues.
ManchesterAges 18–99 - NCT07383025Recruiting
Mavacamten safety study for heart muscle disease in Japan
This study tracks the safety of Mavacamten in people with obstructive hypertrophic cardiomyopathy (a condition where the heart muscle thickens and blocks blood flow). It helps doctors understand how the drug works in everyday use in Japan.
TokyoAges 18 years+ - NCT01076660Recruiting
MRI study to predict sudden cardiac death risk
This trial uses heart MRI images and measurements to look for warning signs that could predict sudden cardiac death. It focuses on people with significantly reduced heart pumping function who are being considered for an ICD to prevent sudden death.
Newark, DelawareAges 21–80 - NCT01091480Recruiting
French heart ultrasound study for hypertrophic cardiomyopathy
This is an observational study (it mainly tracks what happens over time) for people with thickened heart muscle due to hypertrophic cardiomyopathy. You may be eligible if an echocardiogram (heart ultrasound) shows the required thickness and you don’t have certain heart valve disease.
ParisAges 15 years+ - NCT01999140Recruiting
ICD and CRT-D device registry for patients worldwide
This trial is a real-world registry that collects information from people who receive an implantable heart defibrillator or related device. It helps doctors understand how these devices are used and how patients do over time.
Washington D.C., District of ColumbiaAges Any age - NCT02804269Recruiting
Ages 16 to 90 for heart disease information collection
This is a repository program that collects health and imaging-related information to better understand heart (cardiovascular) health and disease. You may be able to join if you are in the age range and share your data for research use.
Singapore, SingaporeAges 16–90 - NCT02445534Recruiting
Registry for cell therapy in non-ischemic dilated heart muscle disease
This is a research registry that follows people with non-ischemic dilated cardiomyopathy (a weakened heart muscle) who are already on the right medications. It helps doctors better understand how cell-based therapy and related care affect heart function over time.
LjubljanaAges 18–65 - NCT02696135Recruiting
Study of Chinese people with hypertrophic cardiomyopathy
This study looks at people with hypertrophic cardiomyopathy (HCM), a heart condition that causes part of the heart muscle to thicken for no clear reason. It will compare how HCM is identified and studied, which may help doctors better understand and manage the condition in Chinese patients.
Beijing, Beijing MunicipalityAges Any age - NCT02641145Recruiting
PET/MRI scans in light-chain amyloid heart disease
This study uses special PET and heart MRI scans to better understand light-chain amyloidosis affecting the heart. The scans may help researchers see how the disease behaves in different patient groups and treatment states.
Boston, MassachusettsAges 18–99
Hear when a new Cardiomyopathies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for cardiomyopathies?
- Yes. Clin2 currently lists 322 recruiting cardiomyopathies studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a cardiomyopathies trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a cardiomyopathies trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.